Order Article Reprints

Lode HN, Ladenstein R, Troschke-Meurer S, Struppe L, Siebert N, Zumpe M, Ehlert K, Huber S, Glogova E, Hundsdoerfer P, et al. Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy. Cancers. 2023; 15(13):3364. https://doi.org/10.3390/cancers15133364

Lode, Holger N., Ruth Ladenstein, Sascha Troschke-Meurer, Linda Struppe, Nikolai Siebert, Maxi Zumpe, Karoline Ehlert, Stefanie Huber, Evgenia Glogova, Patrick Hundsdoerfer, and et al. 2023. "Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy" Cancers 15, no. 13: 3364. https://doi.org/10.3390/cancers15133364

Lode, H. N., Ladenstein, R., Troschke-Meurer, S., Struppe, L., Siebert, N., Zumpe, M., Ehlert, K., Huber, S., Glogova, E., Hundsdoerfer, P., Eggert, A., Zaniewska-Tekieli, A., Balwierz, W., & Wieczorek, A. (2023). Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy. Cancers, 15(13), 3364. https://doi.org/10.3390/cancers15133364